DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NALOXONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Naloxone Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00000192	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000192	Neurobiology of Opioid Dependence: 1 - 1	Withdrawn	Yale University	Phase 2	The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.
NCT00000193	Neurobiology of Opioid Dependence: 2 - 2	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
NCT00000193	Neurobiology of Opioid Dependence: 2 - 2	Withdrawn	Yale University	Phase 2	The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.
NCT00000194	Neurobiology of Opioid Dependence: 3 - 3	Withdrawn	National Institute on Drug Abuse (NIDA)	Phase 2	The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000194	Neurobiology of Opioid Dependence: 3 - 3	Withdrawn	Yale University	Phase 2	The purpose of this study is to study the effects of cycloserine on naloxone-precipitated opiate withdrawal.
NCT00000243	Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone	Terminated	National Institute on Drug Abuse (NIDA)	N/A	Buprenorphine is a drug that may be helpful in treating opioid dependent individuals who were previously maintained on methadone. The purpose of this study is to determine the effects of different doses of buprenorphine/naloxone in treating opioid dependent individuals who were previously maintained on methadone.

Clinical Trial Conditions for Naloxone Hydrochloride

Condition Name

Condition Name for Naloxone Hydrochloride
Intervention	Trials
Opioid-Related Disorders	36
Pain	23
Opioid Dependence	16
Heroin Dependence	14

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Naloxone Hydrochloride
Intervention	Trials
Opioid-Related Disorders	58
Constipation	17
Heroin Dependence	15
Substance-Related Disorders	14

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Naloxone Hydrochloride

Trials by Country

Trials by Country for Naloxone Hydrochloride
Location	Trials
United States	349
China	21
Norway	13
Canada	13
Germany	11

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Naloxone Hydrochloride
Location	Trials
New York	34
California	25
Maryland	23
Connecticut	15
Florida	15

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Naloxone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Naloxone Hydrochloride
Clinical Trial Phase	Trials
Phase 4	55
Phase 3	46
Phase 2/Phase 3	7

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Naloxone Hydrochloride
Clinical Trial Phase	Trials
Completed	139
Recruiting	36
Not yet recruiting	23

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Naloxone Hydrochloride

Sponsor Name

Sponsor Name for Naloxone Hydrochloride
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	48
Mundipharma Research GmbH & Co KG	12
Indivior Inc.	12

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Naloxone Hydrochloride
Sponsor	Trials
Other	203
Industry	91
NIH	57

Export unavailable in trial.
Subscribe for complete access.